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Abstract 
A major hallmark of Alzheimer’s disease (AD) is the formation of neurotoxic 
aggregates composed of the amyloid-β peptide (Aβ). Aβ has been recognized 
to interact with numerous proteins resulting in pathological changes to the 
metabolism of patients with Alzheimer’s disease (AD). One such 
mitochondrial metabolic enzyme is amyloid-binding alcohol dehydrogenase 
(ABAD), where altered enzyme function caused by the Aβ-ABAD interaction, 
is known to cause mitochondrial distress and cytotoxic effects, providing a 
feasible therapeutic target for AD drug development. Here we have 
established a high-throughput-screening (HTS) platform for the identification 
of modulators to the ABAD enzyme. A pilot screen with a total of 6759 
compounds from the NIH Clinical Collections (NCC) and SelleckChem 
libraries and a selection of compounds from the BioAscent diversity collection, 
has allowed validation and robustness to be optimised. The pilot screen 
revealed 16 potential inhibitors  against ABAD with 
favourable physicochemical properties for blood-brain barrier penetration. 
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Abbreviations 
17-HSD10 = 17-hydroxysteroid dehydrogenase type 10  
ABAD  = amyloid-binding alcohol dehydrogenase 
AD  = Alzheimer's disease 
AICD  = amyloid precursor protein intracellular domain 
APP  = amyloid precursor protein 
Aβ  = amyloid-β peptide 
BACE  = β-secretase 
BBB  = blood–brain barrier 
BSA  = bovine serum albumin 
DMSO = dimethyl sulfoxide 
DTT  = dithiothreitol 
ER  = endoplasmic reticulum 
ETC  = electron transport chain 
FAC  = final assay concentration 
HTS  = high throughput screen 
RCCs  = redox cycling compounds 
ROS  = reactive oxygen species 
TEM  = transmission electron microscopy 
S/B  = signal to background  
SDR  = short chain dehydrogenase reductase 
ThT  = thioflavin T 
STD NMR = saturated transfer difference NMR 
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Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia, and with 
current therapies at best palliative the development of a drug that can halt or 
even reverse the progression of AD is an essential goal in order to manage 
this debilitating disease. Despite being identified over 100 years ago the 
underlying cause of AD is a contentious issue with proponents for a number of 
theories. However, the amyloid cascade hypothesis which implicates amyloid-
β peptide (Aβ) as the main causative agent, has been generally accepted.1 
Amyloid binding alcohol dehydrogenase (ABAD, or 17-hydroxysteroid 
dehydrogenase type 10) was first identified as an Aβ binding protein in 1997 
using a yeast two hybrid system.2 A finding which was subsequently 
confirmed using a number of techniques.2–4 ABAD is known to interact with 
the two major plaque forming isoforms of Aβ, namely Aβ(1-40) and Aβ(1-42), 
leading to distortion of the enzyme structure and inhibition of its normal 
function as an energy provider for cells.5,6 In vitro experiments have shown 
that the interaction between ABAD and Aβ is cytotoxic and ABAD’s function is 
altered with a build-up of ROS and toxins leading to mitochondrial 
dysfunction.7 Using site directed mutagenesis and surface plasmon 
resonance (SPR) Lustbader et al.3 identified the LD loop of the ABAD protein 
as the binding site for Aβ, and subsequently synthesised a 28 amino acid 
peptide encompassing this region (amino acids 92-120) that was termed the 
ABAD-decoy peptide (ABAD-DP). Again using SPR it was shown that this 
ABAD-DP could inhibit the binding of ABAD to Aβ(1-40) and Aβ(1-42). 
Significantly, the inhibition of the interaction between ABAD and Aβ by ABAD-
DP was shown to translate into a cytoprotective effect in cell culture 
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experiments.8 Cultured wild type cortical neurons exposed to Aβ(1-42) 
showed a significant increase in cell death, as measured by cytochrome-c 
release, whilst those pre-incubated with the ABAD-DP did not.8 Critically for 
this work demonstrated that inhibition of the ABAD-Aβ interaction may offer a 
novel therapeutic avenue for the treatment of AD.  
 
Other than the disruption of the ABAD-Aβ interaction, there is a second 
approach which may hold merit in treating AD; the direct modulation of ABAD 
activity. In vitro experiments with SHSY-5Y cells administered with the ABAD 
inhibitor, AG18051, show a reduction in mitochondrial dysfunction and 
oxidative stress associated with the interaction between ABAD and Aβ, and 
are protected from Aβ mediated cytotoxicity.9 Suggesting that inhibition of 
ABAD may also be a viable therapeutic approach in the treatment of 
complexities that exist within AD. In order to screen and identify new 
efficacious drug-like inhibitors we have already developed an ABAD activity 
assay,10 utilising the loss of absorbance of the enzyme’s cofactor NADH (at 
340 nM) as ABAD converts it to NAD+ as its readout. However, as very few 
modulators of ABAD activity have been reported and with limited compound 
diversity as starting points for those that have, we optimised this assay further 
to achieve an improved, robust assay amenable to high-throughput screening 
(HTS) on a 384-well plate scale.  
 
Materials and Methods   
All aqueous solutions were prepared with deionized water (Millipore, UK) and 
all chemicals purchased from Sigma Aldrich, UK unless stated. ABAD protein 
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was expressed and purified as described in Aitken et al. 2016.11 The initial 96-
well plate screening assay conditions are described in Hroch et al. 2016.10 
Assay buffer used contains: 10 mM Tris.HCl (pH 7.4), 150 mM NaCl, 1 mM 
DTT, 0.005 % Tween and 0.01 % BSA. As indicated for some experiments 
the assay buffer was supplemented with 100 units/ml bovine liver catalase. All 
experiments were conducted in clear bottom 384-well low volume microplates 
(Corning) with a final assay volume of 20 µl and the reaction progress was 
monitored by oxidation of NADH as determined by reduction in absorbance at 
340 nm read on the EnVision plate reader (PerkinElmer).  
 
Acetoacetyl-CoA Enzyme Kinetics  
To determine the kinetics for acetoacetyl-CoA and the effect of ABAD 
concentration upon reaction rate, a matrix titration experiment was set up. 
Previously determined conditions10 were used with a fixed concentration of 
700 µM NADH and a starting concentration of up to 200 µM acetoacetyl-CoA. 
Doubling dilutions of acetoacetyl-CoA were then coupled with doubling 
dilutions of ABAD, which started with a maximum concentration of 40 nM. 
Data collected from the experiment was analysed using a standard template 
from which reaction progress curves were analysed to calculate initial 
velocities and obtain Km values using the Michaelis-Menten equation (XLFit, 
ID Business Solutions).  
 
NADH Enzyme Kinetics 
To determine the kinetics for NADH and the effect of ABAD concentration 
upon reaction rate a matrix titration experiment was set up. Previously 
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determined conditions10 were used, 120 µM acetoacetate and a starting 
concentration of up to 1000 µM NADH. Doubling dilutions of NADH were then 
coupled with doubling dilutions of ABAD, which started with a maximum 
concentration of 40 nM. Data were analysed as described previously.  
 
Assay Development 
An optimal ABAD concentration was established using a range of 
concentrations from 0.625, 1.25, 2.5 and 5 nM with measurements taken up 
to 60 minutes after the reactions were started to capture the full extent of the 
reaction linearity. Assay DMSO tolerance was tested from 20 % using a 10 
point serial dilution with reads being taken up to 60 minutes as before. 
Reagent stability experiments were carried out whereby reactions were 
started at times of 0, 1, 2, 4 and 8 hours after reagent preparation. All 
reagents were maintained at room temperature throughout the course of the 
experiment.  
 
Compound Screening  
For primary screening an endpoint assay format was adopted in which an 
Echo acoustic liquid dispenser (Labcyte) was used to transfer 20 nl of either 
reference standard, DMSO control (0.5 % final assay concentration (FAC)) or 
test compounds (10 µM FAC) to the assay plate. 10 µL of ABAD enzyme in 
assay buffer (2.5 nM FAC) was then added to the plates using the Preddator 
liquid handling robot (Redd and Whyte) and plates were incubated at room 
temperature for 15 minutes. 10 µL of substrate mixture (100 µM acetoacetyl-
CoA and 100 µM NADH FAC) was added with the Preddator.  To start the 
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reaction and the plates were left to incubate for 35 minutes at room 
temperature before the absorbance at 340 nm was read on the EnVision plate 
reader (PerkinElmer). For kinetic assay format follow up experiments the 
same protocol was adopted but the absorbance at 340 nm was monitored 
constantly for 45 minutes from immediately after the reaction was started.  
 
Physiochemical predictions 
Published values were obtained for the NCC/Selleckchem hits (where 
available) from DrugBank (http://www.drugbank.com) and where there were 
no published values, predictions were made using ChemAxon Marvin suite 
(http://www.chemaxon.com). 
 
Results and Discussion 
To miniaturise our 96-well plate enzyme activity assay into one suitable for 
HTS, i.e. 384-well plate, we have taken a number of considerations into 
account. Firstly, our assay needed to be sensitive to inhibitors with a relevant 
and developmentally tractable mechanism of action. This required 
characterisation of the ABAD enzyme kinetics using the buffering conditions 
and 384-well microplates that were intended for use in the screen. Substrate 
concentrations for screening were then selected based upon which substrate 
binding site was deemed most tractable for discovering selective and potent 
inhibitors. Typically the substrate would be screened at or close to its Km, as 
this provides a balanced chance of finding competitive, non-competitive or 
uncompetitive inhibitors, and with regards to ABAD, acetoacetyl-CoA was 
considered to be the best substrate to target, because NADH is a ubiquitous 
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cofactor for numerous proteins. As such a concentration of NADH in excess of 
its experimentally determined Km was deemed the best approach to de-
sensitise the assay to NADH competitive molecules. In addition to the 
concentration of substrates the concentration of enzyme is also vitally 
important in a screening assay. It must be high enough so that the enzyme is 
stable in solution over the course of the assay and can produce enough 
substrate turnover to reliably monitor reaction progress. However, it should 
not be too high that the reaction runs too quickly, thus allowing effective 
monitoring of the linear steady-state of the reaction. A low protein 
concentration should also avoid additional issues such as excessive protein 
requirement for large scale screening purposes or encountering limitations in 
the determination of IC50 for high affinity inhibitors too early in a development 
programme.11 Finally, the screening assay needed to provide a robust reliable 
signal that allowed a significant compound effect to be identified from non-
effect. This was determined by the Z’-value, a screening statistic that takes 
into consideration the signal window and the standard deviation with an ideal 
value of between 0.5 and 1 for a robust assay.12  
It was hypothesised that a larger signal to background ratio would be 
seen if the assay could be adapted to be measured as a fluorometric assay. 
Additionally, moving to a measurement at longer wavelengths would help 
reduce the potential for compound interference of the assay signal. Several 
methods were explored to utilise a fluorescence based screening method, 
including direct measurement of NADH fluorescence; however this resulted in 
very poor Z’ values and signal. An alternative approach was to try all three 
commercially available Amplite fluorimetric kits (AAT Bioquest) but these 
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resulted in signal saturation at all concentrations of NADH/NAD+ tested 
(despite kit guidelines) or proved to be cumbersome for HTS purposes with 
many addition steps whilst still resulting in poor Z’ values. As our absorbance 
assay produced very high Z’ values indicating the assay was very robust, it 
was decided to reject this hypothesis and accept the lower signal to 
background ratio and continue with an absorbance HTS assay.  
 
Enzyme Kinetics 
To determine the kinetics for acetoacetyl-CoA and NADH and to investigate 
the reaction rate dependence of ABAD concentration a matrix titration of 
acetoacetyl-CoA vs. ABAD and NADH vs. ABAD was conducted using our 
previously determined buffering conditions.10 Fixed concentrations of either 
NADH (700 µM) or acetoacetyl-CoA (200 µM) were used, while the second 
substrate was titrated respectively. Doubling dilutions of substrate were then 
coupled with doubling dilutions of ABAD starting with a maximum 
concentration of 40 nM. Activity time courses and initial velocities were 
obtained and after optimisation it was decided to use a lower concentration of 
NADH (100 µM), which is still in excess of Km and a higher starting 
concentration of acetoacetyl-CoA (800 µM) in order to obtain a full response. 
Figure 1A and 1B demonstrate the final kinetic data, where the Km for 
acetoacetyl-CoA was 117 ± 28 µM and a Km of 32.96 ± 4.47 µM for NADH 
was achieved.  
Previous findings10 suggested that NADH is required in excess of its 
Km in order to minimise the sensitivity of the assay to NADH competitive 
inhibitors. However, a concentration of NADH that was too high resulted in a 
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very high level of NADH background signal, this decreased the signal change 
relative to background that was observed by the activity of ABAD. The 
concentration of ABAD was also assessed; an optimal concentration 
produced a suitable change in absorbance, whilst still remaining in the initial 
velocity phase for an appropriate amount of time. This resulted in an 
increased signal to background and improved Z-prime. Four concentrations of 
ABAD were investigated (0.625, 1.25, 2.5 and 5 nM), where 0.625 nM and 
1.25 nM ABAD produced very little signal window and the reaction at 5 nM 
was extremely fast. 2.5 nM ABAD produced a functional signal whilst it 
remained in the initial velocity phase for approximately 30-45 minutes. The 
NADH concentration had little effect on this experiment, especially at the 
higher concentrations indicating that the reaction was more dependent on 
acetoacetyl-CoA. It was determined that 62.5 µM and 125 µM NADH 
produced consistent results, therefore the excess concentration of NADH 
used in the final assay was 100 µM. 
 
DMSO Tolerance 
As most screening compounds are solubilised in DMSO, the tolerance of 
the enzyme assay to this solvent was assessed. Industry standard assays 
require a tolerance of at least 0.5% DMSO.13 Using the established kinetic 
conditions DMSO tolerance was evaluated up to 20% of DMSO. Our 
ABAD activity assay was found to be tolerant up to approximately 2.5% 
DMSO, although less than 1% DMSO is more favourable (Figure 2A).  
 
Reagent Stability 
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For logistical HTS purposes it is important to understand for how long and 
under what conditions the various assay reagents are stable. Firstly, enzyme 
and substrate solutions were prepared in assay buffer and maintained at room 
temperature. Reactions were then started at time 0, 1, 2, 4 and 8 hour 
intervals after preparation with absorbance values (Figure 2B) used to 
compare Z’ values and signal to background values for each time point 
(Figure 2C and 2D). In addition to this, the effect of freeze/thawing ABAD 
was also assessed. These experiments confirmed that while the reagents 
used for this assay are stable for a prolonged length of time when stored 
appropriately, when prepared and kept at room temperature they are stable 
for up to two hours and that ABAD is not stable when freeze/thawed. 
Furthermore, the addition of bovine serum albumin (BSA) appeared to 
stabilise the enzyme and produced Z’ values of 0.7-0.75 and the reaction 
still appeared in the initial velocity phase during the 45 minute incubation 
period so it was decided to also include 0.01% BSA in the assay buffer. 
Collectively, these assay variations allowed an optimised 384-well 
plate scale (~20 L) assay to be established, with more than suitable Z’ 
values. The key criteria are shown in Table 1. 
 
Robustness Set Testing  
In order to evaluate what type of undesirable screening compounds our assay 
was susceptible to pick up as false positives, 118 small molecules with known 
HTS liabilities14,15 were screened at two concentrations (10 and 1 µM). There 
was a percentage hit rate of 27 % of compounds at 10 µM and 9 % of 
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compounds at 1 µM, the full breakdown of the classification of compounds 
can be found in Table 2. 
A very high percentage (81 % at 10 µM and 38 % at 1 µM) of the redox 
cycling compounds (RCCs) appeared to inhibit the effect of ABAD. The buffer 
for this assay contains the reducing agent DTT. RCCs generate H2O2 in the 
presence of strong reducing agents and H2O2 can indirectly inhibit the 
catalytic activity of proteins.16 This is often a major source of false positives 
when performing a HTS. Identifying that a target is sensitive to inhibition by 
RCCs during assay development allows steps to be taken to either minimise 
the sensitivity to RCCs through optimisation of the assay buffer or to design a 
screening triage process that identifies and eliminates RCCs.17 Unfortunately, 
despite alternative agents being available it was not possible to remove or 
replace DTT from the assay buffer as this reagent was found to be essential 
for protein stability; however, addition of catalase which degrades H2O2, 
abolished RCC-mediated inhibition of ABAD (Table 2). The addition of 
catalase to the assay buffer did negatively impact upon the S/B and Z’ scores 
so its inclusion was not considered ideal for primary screening however it was 
used in lower throughput follow up assays with a higher replication level to 
identify and eliminate RCCs.  
 
Primary Validation Screen 
To further assess the performance of the ABAD assay, a small HTS of 1564 
known bioactive compounds from the NIH Clinical Collections (NCC) and 
Selleckchem, FDA-approved Drug libraries, combined with 5195 diverse 
compounds from the BioAscent Compound Cloud 
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(http://www.bioascent.com/compoundcloud/) were screened producing 262 
and 508 potential hits respectively, where hit compounds were classed as 
those producing a >20 % effect on ABAD inhibition. The screen proved very 
robust, with Z’ values between 0.75 and 0.77 and CV% across the plates 
varying between 0.4 and 2.6 %. Signal to background varied between 1.40 
and 1.49. These 770 potential hit compounds were then screened kinetically 
against ABAD to identify compounds, which genuinely inhibit product 
formation rather than simply absorb light at 340 nM and are therefore false 
positives when screened in the endpoint assay.  De-selection of these hits 
using the catalase assay to remove any redox cycling compounds left 9 
confirmed hits from the BioAscent collection and 8 hits from the NCC/ 
SelleckChem libraries (Table 3), final hit rates of 0.17% and 0.5% 
respectively. Best hit compound pIC50 curves for ABAD ± catalase can be 
found in supplementary information (Figure S1 and Table S1). A future step 
will be to obtain freshly prepared samples of these hit compounds and test 
them in orthogonal ABAD assays to validate target engagement.  
A key aspect of any potential ABAD inhibitor is that in order to be of 
therapeutic value in AD they should be CNS penetrant. As the NCC and 
Selleckchem libraries are composed of a focussed set of FDA-approved drugs 
and NIH clinical candidates, these properties have already been published.18 
Physiochemical properties were calculated for the BioAscent compounds 
using ChemAxon software, where calculator Plugins were used for structure 
property prediction and calculations,19 to give a direct comparison to those 
published for the NCC/Selleckchem hits (Table 3). Notably all of these hit 
compounds appear to be in good agreement with the optimal values for CNS 
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bioavailability20,21, with the predicted aqueous solubility values also being 
satisfactory for many of the compounds. The optimal values for CNS 
penetrance were taken as MW ≤500, logP ≤5, HBA ≤7, HBD ≤3, TPSA ≤90 Å, 
logS7.4 ≤-4, logD7.4 = 0-3.20,21 
The BioAscent compounds were selected principally on the basis of 
diversity, and so structure-activity relationships are limited in the resulting 
data. However, future work may include purchasing structurally similar 
scaffolds from their larger 100,000 library and once the hit compounds have 
been further validated, these could be acquired to develop SAR further.  
The NCC/Selleckchem hits revealed several interesting molecules that have 
already been used and characterised as drugs for CNS diseases. For 
example, Liothyronine (a synthetic form of the thyroid hormone) has 
previously been used to treat hyperthyroidism and myxoedema, as well as in 
an augmentation strategy in treating major depressive disorder in combination 
with antidepressants.22 However, there are links to thyroid replacement 
therapy and the advancement of AD symptoms, therefore this drug may not 
be the most promising starting point for a potential therapeutic for AD.23  
Another former FDA approved drug identified in our screen was 
Alosetron.HCl (Lotronex, GSK). This compound blocks serotonin by 
targeting the 5-HT3 receptor. This drug was shown to be effective in 
treating irritable bowel syndrome, but was officially withdrawn from the 
market in 2000 due to adverse side effects before being re-introduced in 
2002 for patients who did not respond to conventional treatments.24 
Compounds which act against serotonin have already been implicated as 
a potential therapeutic strategy for Alzheimer’s disease due to the role of 
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serotonin-receptors in cognition and memory,25 and an increase in 
serotonin signalling was associated with less Aβ accumulation in 
cognitively normal individuals.26 With 5-HT3 antagonists capable of freely 
passing the blood–brain barrier, and already implicated in other 
neurological conditions (Schizophrenia and anxiety)24 analogues based on 
this structure may prove to be more promising as a therapeutic agent 
against ABAD.  
Ellagic acid, a natural phenol antioxidant and taxifolin or silymarin, a 
member of the flavonoid family are two of the more commercially available 
hits from this screen. Using TEM and Thioflavin T, a β-sheet dye that 
fluoresces in the presence of Aβ aggregates, Taxifolin has been shown to 
inhibit Aβ aggregation, although the mechanism of action is still to be 
determined.27  
Although not the most promising compound within the 16 hit 
compounds, Raloxifene.HCl, appeared as a hit in both the NCC and Selleck 
libraries, however it was also the least active. Raloxifene has been licenced 
since 1997 (Evista, Eli Lilly) and used to treat osteoporosis in post-
menopausal women.28 Raloxifene has already participated in a small clinical 
trial for AD where it was shown that a large dose of the drug resulted in the 
reduced risk of cognitive impairment in postmenopausal women.29 It is 
already known that the inhibition of ABAD restores the amyloid-β-mediated 
deregulation of estradiol,9 and with Raloxifene classed as a selective estrogen 
receptor modulator this compound proves to be very interesting and its 
analogues require further investigation as possible therapeutics against 
ABAD. 
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Overall we have optimised and evaluated our ABAD enzyme activity 
assay into a robust 384- well plate HTS, and used it to identify several novel 
molecules that modulate ABAD activity and have physicochemical properties 
suggesting CNS penetration. These could be developed further into lead like 
candidates against ABAD, a therapeutic target in AD. We have also identified 
several FDA approved drugs that with further investigation may be classed as 
re-purposed drugs if they prove to have a role in AD prevention/therapy.  
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Table 1: Assay development summary table. This table highlights key 
HTS criteria met and established for our ABAD enzyme activity assay.   
HTS Criteria 
Experimentally Established Final 
Assay Values 
Assay format 384-well-plate (clear) 
Homogeneous assay No wash steps 
Reaction volume 20 µL 
Selected Substrate Concentrations 
100 µM acetoacetyl-CoA, 100 µM 
NADH 
Full Plate Signal/Background 1.5 
Full Plate Z’ value >0.7 
Tolerance to DMSO Tolerant up to ~2.5% DMSO 
Minimal signal pattern on plates 
CV<10% 
<3 % 
Incubation times up to 4 hours 
Incubate for 35-40 minutes before 
reading 
Buffer composition 
10 mM Tris.HCl, 150 mM NaCl, 
pH7.4, 1 mM DTT, 0.005 % Tween, 
0.01% BSA 
Substrate Km 
100 µM acetoacetyl-CoA, 20 µM 
NADH 
Reagent Stability 
Over 8 hours when reagents are 
stored appropriately, but 2 hours 
stability at room temperature 
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Table 2: Robustness screening set 
Unwanted 
physical 
property 
Number of 
Compounds 
Number 
active 
at 10 
µM 
Number  
active 
at 1 µM 
Number 
active 
at 10 µM + 
Catalase 
(100 
units/well) 
Number  
active 
at 1 µM +  
Catalase 
(100 
units/well) 
Aggregators 35 11 1 4 1 
Chelating 10 1 0 0 0 
Coloured 10 0 0 0 0 
Fluorescent 17 1 2 0 0 
Redox 
cycling 
21 17 8 0 0 
Luciferase 15 2 0 1 0 
Reactive 10 0 0 0 0 
Total 118 32 11 5 1 
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Table 3: Physiochemical properties of 16 best hit compounds 
Compound 
Number 
Compound 
ID and Drug 
Name where 
applicable 
Structure MW 
pIC50 no 
catalase 
pIC50 with 
catalase 
logP HBA/HBD 
TPSA 
(Å) 
logS 7.4 logD 7.4 
Optimal 
Properties 
20,21 
- - ≤500 - - ≤5 ≤7/≤3 ≤90 ≤ -4 0-3 
1 BCC0060072 
 
318.14 
4.5 ± 
0.03 
4.4 ± 0.04 4.88 3/1 50.69 -4.38 2.25 
 23 
2 
BCC0081684 
 
393.14 
5.0 ± 
0.07 
4.9 ± 0.05 3.97 4/3 63.93 -4.47 2.13 
3 BCC0087550 
 
237.12 
5.0 ± 
0.03 
4.9 ± 0.05 4.88 1/0 26.03 -5.05 5.02 
4 BCC0090417 
 
328.25 
4.3 ± 
0.02 
4.3 ± 0.07 4.39 1/2 41.99 -5.35 3.86 
 24 
5 BCC0100281 
 
324.17 
4.6 ± 
0.03 
4.4 ± 0.05 2.13 5/1 83.73 -2.27 2.19 
6 BCC0083458 
 
322.14 
4.1 ± 
0.03 
4.0 ± 0.07 2.06 5/2 74.33 -3.17 0.60 
7 BCC0082593 
 
393.14 
4.2 ± 
0.03 
4.1 ± 0.07 3.75 4/0 58.45 -4.99 3.36 
 25 
8 BCC0066281 
 
355.14 
4.3 ± 
0.04 
4.2 ± 0.05 3.05 5/1 66.02 -3.87 3.05 
9 BCC0011022 
 
236.09 
4.5 ± 
0.05 
- 3.05 2/2 41.13 -5.05 3.05 
10 
SAM002548975 
(Raloxifene HCl) 
 
473.16 2.7 - 5.69 5/2 70.00 -6.00 5.34 
 26 
11 
SAM003107539 
(Liothyronine) 
 
350.79 4.5 - 2.80 4/3 92.78 -4.5 2.76 
12 
SAM001246778 
(Taxifolin) 
 
304.96 4.3 - 1.82 7/5 127.45 -2.18 1.65 
13 
SAM001246760 
(Taxifolin) 
 
304.96 4.0 - 1.82 7/5 127.45 -2.18 1.65 
 27 
14 
SAM001246782 
(Alosetron HCl) 
 
292.17 4.1 - 0.98 2/1 53.92 -2.80 1.19 
15 
S1227 
(Raloxifene HCl) 
 
473.16 
5.0 ± 
0.05 
4.9 ± 0.07 5.69 5/2 70.00 -6.00 5.34 
16 
S1327 
(Ellagic Acid) 
 
302.01 
4.8 ± 
0.05 
4.6 ± 0.04 2.32 6/4 133.52 -2.60 -1.83 
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Figure Legends: 
 
Figure 1: Initial velocity curves for ABAD (2.5 nM) under increasing 
concentrations of NADH (A) and acetoacetyl-CoA (B), where Km values= 
32.96 ± 4.47 µM and 117 ± 28 µM for NADH and acetoacetyl-CoA were 
calculated (n=3).   
 
Figure 2: DMSO tolerance and reagent stability testing. (A) Starting 
concentration of 20% DMSO with a 10 point 1:2 dilution. The DMSO optimal 
assay concentration was found to be 1% DMSO or lower. (B-D) Comparison 
of reagent stability, where samples in the left panel are left at room 
temperature and right panel where samples are at 4°C over an 8 hour 
sample preparation time course. Reliability was measured by monitoring 
changes to the maximum and minimum absorbance values (B), Z-primes (C) 
and S/B (D).  
 
 
 
